{
    "organizations": [],
    "uuid": "8e9577682e6251b991ad3c7aa1a6fbbf80a5562a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-anhui-anke-biotechnology-group-to/brief-anhui-anke-biotechnology-group-to-acquire-approval-for-clinical-trial-and-technique-of-monoclonal-antibody-injection-idUSL4N1PK4B2",
    "ord_in_thread": 0,
    "title": "BRIEF-Anhui Anke Biotechnology Group to acquire approval for clinical trial and technique of monoclonal antibody injection",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 25(Reuters) - Anhui Anke Biotechnology Group Co Ltd\n* Says co plans to acquire approval for clinical trial and technique of a kind of monoclonal antibody injection from Jiangsu Aosaikang Pharmaceutical Co Ltd (seller), at the price of 50 million yuan\n* Say co also needs to pay sales commissions to seller\nSource text in Chinese: goo.gl/m4pD9h\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-01-25T20:20:00.000+02:00",
    "crawled": "2018-01-26T21:20:04.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "anhui",
        "anke",
        "biotechnology",
        "group",
        "co",
        "ltd",
        "say",
        "co",
        "plan",
        "acquire",
        "approval",
        "clinical",
        "trial",
        "technique",
        "kind",
        "monoclonal",
        "antibody",
        "injection",
        "jiangsu",
        "aosaikang",
        "pharmaceutical",
        "co",
        "ltd",
        "seller",
        "price",
        "million",
        "yuan",
        "say",
        "co",
        "also",
        "need",
        "pay",
        "sale",
        "commission",
        "seller",
        "source",
        "text",
        "chinese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}